Analysis showed that there was a significant association between high ANRIL expression and poor OS in patients with cancer (pooled HR = 2.12, 95% CI: 1.78–2.53, P < 0.0001) by a fixed-effects model (I2 = 0%, P = 0.654) (Figure 4). This evidence concerns the gene CDKN2B-AS1 and cancer.